Department of Neurology; Memorial Multiple Sclerosis Center, UMass Memorial Medical Center
Amino Acids, Peptides, and Proteins | Biological Factors | Immune System Diseases | Nervous System Diseases | Pathological Conditions, Signs and Symptoms
Several clinical, immunological and radiological biomarkers have been shown to predict the disease course of multiple sclerosis (MS).One potential serum marker is the gMS-Classifier1, which is composed of IgM anti-Glc antibodies, namely anti-GAGA 2,3,4 and 6. Previous work demonstrated that the gMS-Classifier1 could not predict early conversion to clinically definite MS in a cohort of clinically isolated syndrome (CIS) patients, but predicted Expanded Disability Status Scale (EDSS) progression. Significance, however, was dependent on covariates, and confirmation in an independent study was required. The aim of this study was to test if the gMS-Classifier1 could predict early disability progression in a large multicenter cohort of patients with CIS or relapse-onset MS.
multiple sclerosis, biomarkers, gMS-Classifier1
Rights and Permissions
© The Author(s), 2018. Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
DOI of Published Version
Mult Scler. 2019 Jun;25(7):1010-1011. doi: 10.1177/1352458518798048. Epub 2018 Aug 31. Link to article on publisher's site
Multiple sclerosis (Houndmills, Basingstoke, England)
van Rossum, Johannis A.; Killestein, Joep; Villar, Luisa M.; Riskind, Peter N.; Freedman, Mark S.; and Teunissen, Charlotte, "gMS-Classifier1 does not predict disability progression in multiple sclerosis" (2019). Open Access Articles. 3892.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License